Investments
1Portfolio Exits
1About Integrium Clinical Research
Integrium is a full-service Clinical Proof of Concept (PoC) Firm focused within the therapeutic areas of Cardiovascular, Metabolic, Renal, Inflammatory, Dermatology, Wound Healing, Regenerative, and Orphan Disease. Although we have the scientific, medical, operational, and regulatory expertise to cover all stages of clinical development (Phase I-IV), we are Experts in the Strategy, Design and Execution of Clinical PoC Trials.
Integrium Clinical Research Headquarter Location
100 E. Hanover Avenue Suite 401
Cedar Knolls, New Jersey, 7927,
United States
877-332-1572
Expert Collections containing Integrium Clinical Research
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Integrium Clinical Research in 1 Expert Collection, including Pharma Startups.
Pharma Startups
5,090 items
Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.
Integrium Clinical Research Investments
1 Investments
Integrium Clinical Research has made 1 investments. Their latest investment was in Oncolix as part of their Series A on January 1, 2015.
Integrium Clinical Research Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
1/22/2015 | Series A | Oncolix | $4.51M | Yes | 2 |
Date | 1/22/2015 |
|---|---|
Round | Series A |
Company | Oncolix |
Amount | $4.51M |
New? | Yes |
Co-Investors | |
Sources | 2 |
Integrium Clinical Research Portfolio Exits
1 Portfolio Exit
Integrium Clinical Research has 1 portfolio exit. Their latest portfolio exit was Oncolix on August 07, 2017.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
8/7/2017 | Reverse Merger | 1 |
Date | 8/7/2017 |
|---|---|
Exit | Reverse Merger |
Companies | |
Valuation | |
Acquirer | |
Sources | 1 |